Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY-201: SX-682 Plus Enzalutamide in ARPI-Resistant mCRPC
NCT06228053Phase 2Recruiting
- Sponsor
- Syntrix Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SX-682 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Syntrix Pharmaceuticals. Started Nov 2024; status: recruiting.
02
Drugs
SX-682
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06228053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228053.